For Healthcare Professionals

Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer


About the study

The primary objective of the dose escalation (phase 1) part of the study is: • To assess the safety, tolerability and pharmacokinetics (PK) of the antibody drug conjugate (ADC) REGN5093-M114 in order to determine a maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) of REGN5093-M114 in patients with mesenchymal epithelial transition factor (MET) overexpressing non-small cell lung cancer (NSCLC). The primary objective of the dose expansion (phase 2) part of the study is: • To assess preliminary anti-tumor activity of REGN5093-M114 in MET-overexpressed NSCLC as measured by the objective response rate (ORR) The secondary objective of the dose escalation (phase 1) part of the study is: • To assess preliminary anti-tumor activity of REGN5093-M114 as measured by the ORR The secondary objective of the dose expansion (phase 2) part of the study is: • To assess the safety, tolerability profile, and PK of REGN5093-M114 ADC and total antibody in each expansion cohort The secondary objectives of both phases of the study are: To evaluate other measures of preliminary anti-tumor activity To assess immunogenicity to REGN5093-M114

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Key Inclusion Criteria:

  1. Histologically confirmed NSCLC that is at advanced stage for which there are no approved therapies available expected to confer clinical benefit as defined in the protocol
  2. Willing to provide tumor tissue from newly obtained biopsy from tumor site. Newly obtained biopsies at tissue screening are required. An archival sample can be accepted only after discussion with the medical monitor and if the sample is not more than 6 months old and obtained after completion of the last therapy. The enrollment of patients will be based on an immunohistochemistry (IHC)-based assay using freshly obtained tumor biopsies or an archival biopsy as described above. Only patients with MET overexpressing tumors by central IHC analysis will be enrolled. For expansion cohorts only: tumor site for biopsy must not have been irradiated previously and must not be the only measurable lesion.
  3. Tumor must overexpress MET protein as defined in the protocol by central IHC analysis
  4. For expansion only: At least one lesion that is measurable by RECIST 1.1. Tumor lesions in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions after radiation.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Adequate organ and bone marrow function as defined in the protocol


Key Exclusion Criteria:

  1. Has received treatment with an approved systemic therapy or has participated in any study of an investigational agent or investigational device within 2 weeks or 5 half-lives of the prior treatment, whichever is shorter with a minimum of 7 days from the first dose of study therapy
  2. Has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities resulting from prior therapy except as described in the protocol
  3. Has received radiation therapy or major surgery within 14 days of first administration of study drug or has not recovered from adverse events as defined in the protocol
  4. Another malignancy that is progressing or requires active treatment except as noted in the protocol
  5. Untreated or active primary brain tumor, central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
  6. Encephalitis, meningitis, organic brain disease (eg Parkinson's disease) or uncontrolled seizures in the year prior to first dose of study therapy
  7. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; or diagnosis of immunodeficiency as defined in the protocol

NOTE: Other protocol-defined Inclusion/ Exclusion criteria apply

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 844-734-6643Email iconEmail Study Center

Study’s details


Advanced NSCLC

Age (in years)



Phase 1/Phase 2

Participants needed


Est. Completion Date

Dec 2, 2026

Treatment type



Regeneron Pharmaceuticals identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.